Improved quantitative analysis of primary bone marrow megakaryocytes utilizing imaging flow cytometry

Lisa M Niswander1, Kathleen E McGrath, John C Kennedy

  • 1Department of Pediatrics, Center for Pediatric Biomedical Research, University of Rochester Medical Center, Rochester, New York, 14642; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, 14642.

Insights

Imaging flow cytometry (IFC) offers a new method to study megakaryocytes (MKs), crucial for platelet production. This technique overcomes challenges in analyzing MKs, aiding research into thrombocytopenia.

Area of Science:

  • Hematology
  • Cell Biology
  • Biotechnology

Background:

  • Thrombocytopenia, a condition of low platelet count, often results from bone marrow injury and impaired megakaryocyte (MK) function.
  • Studying primary MKs is difficult due to their rarity in bone marrow and complex maturation, hindering the development of effective thrombocytopenia treatments.

Purpose of the Study:

  • To evaluate the utility of imaging flow cytometry (IFC) for analyzing primary murine megakaryocytes (MKs).
  • To address existing technical limitations in conventional flow cytometry for MK analysis.
  • To establish a reproducible method for quantifying MKs and their ploidy in vivo.

Main Methods:

  • Isolation of primary MKs from murine bone marrow.
  • Application of imaging flow cytometry (IFC) on the ImageStream(X) platform.
  • Analysis of MKs at steady-state and following radiation-induced bone marrow injury.

Main Results:

  • IFC effectively addresses challenges posed by MK size variation and shared surface markers with platelets.
  • IFC enables reproducible and efficient quantification of primary murine MK frequency.
  • IFC accurately assesses MK ploidy distribution in both steady-state and injury conditions.

Conclusions:

  • IFC provides a powerful tool for analyzing the full spectrum of maturing MKs in the bone marrow.
  • This method enhances the understanding of megakaryopoiesis and platelet production.
  • IFC applications hold promise for developing novel therapeutic strategies for thrombocytopenia.